Jean Klášterský
About
In The Last Decade
Jean Klášterský
437 papers receiving 11.9k citations
Hit Papers
Peers
Comparison fields: 5 of 163
- Oncology 7.0k
- Clinical Biochemistry 3.2k
- Epidemiology 3.2k
- Pharmacology 2.4k
- Pulmonary and Respiratory Medicine 2.4k
Countries citing papers authored by Jean Klášterský
This map shows the geographic impact of Jean Klášterský's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean Klášterský with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean Klášterský more than expected).
Fields of papers citing papers by Jean Klášterský
This network shows the impact of papers produced by Jean Klášterský. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean Klášterský. The network helps show where Jean Klášterský may publish in the future.
Co-authorship network of co-authors of Jean Klášterský
This figure shows the co-authorship network connecting the top 25 collaborators of Jean Klášterský. A scholar is included among the top collaborators of Jean Klášterský based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean Klášterský. Jean Klášterský is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 12 | |
| 2 | 1 | |
| 3 | 1 | |
| 4 | Oral empiric treatment and early hospital discharge for febrile neutropenic cancer patients predicted at low-risk by the MASCC score: experience at the Institut Jules Bordet | 1 |
| 5 | 5 | |
| 6 | 16 | |
| 7 | Prognostic factors analysis for response to chemotherapy and survival in a prospective cohort of patients with unresectable locoregional non small cell lung cancer initially treated by induction chemotherapy | 2 |
| 8 | Taxanes in lung cancer therapy | 0 |
| 9 | Phase I study of Amphotericin B lipid complex with ABLC pharmacokinetics in patients receiving antineoplastic therapy | 12 |
| 10 | 25 | |
| 11 | 13 | |
| 12 | Empiric antimicrobial therapy for febrile granulocytopenic cancer patients | 10 |
| 13 | La publication scientifique. | 4 |
| 14 | Serum bactericidal activity of ampicillin and mezlocillin with and without sulbactam | 8 |
| 15 | Combination antibiotic therapy in the compromised host | 16 |
| 16 | Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. The EORTC international antimicrobial therapy project group. breakdown → | 351 |
| 17 | [Controlled study of oral administration of antibiotics in the preparation of digestive surgery (author's transl)]. | 2 |
| 18 | ETUDE COMPARATIVE DE LA TICARCILLINE ET DE LA CARBENICILLINE COMME TRAITEMENT PROPHYLACTIQUE ASSOCIE A LA CHIRURGIE CARCINOLOGIQUE CERVICO FACIALE | 2 |
| 19 | ADVANCES IN AMINOGLYCOSIDE THERAPY: AMIKACIN | 2 |
| 20 | Concentration of gentamicin in bronchial secretions of children with cystic fibrosis of tracheostomy. (Comparison between the intramuscular route, the endotracheal instillation and aerosolization). | 8 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.